Loading...
Stage III colon cancer (lymph node involvement without distant metastases) is typically treated with adjuvant chemotherapy. Treatment decisions are currently based on tumor stage classification, but further classification of tumors based on molecular biomarkers is sought to improve prognosis determination and guide therapy.
In the current analysis, investigators conducted molecular testing of stage III colorectal tumors in 2720 patients undergoing adjuvant therapy with FOLFOX or FOLFOX plus cetuximab. They classified tumors into five subtypes. Mismatch repair (MMR) status was characterized as proficient (pMMR) or deficient (dMMR). The pMMR tumors were classified as BRAF-mutated (7% of the entire cohort), KRAS-mutated (35%), or lacking mutati…